Moderna Future Growth

Future criteria checks 1/6

Moderna is forecast to grow earnings and revenue by 17.7% and 6.7% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be -24.3% in 3 years.

Key information

17.7%

Earnings growth rate

17.8%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	6.7%
Future return on equity	-24.3%
Analyst coverage	Good
Last updated	26 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BIT:1MRNA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3,798	-2,603	-2,324	-1,560	20
12/31/2025	3,009	-3,415	-3,168	-2,615	25
12/31/2024	3,302	-3,545	-3,524	-2,892	24
9/30/2024	5,081	-2,224	-3,956	-3,207	N/A
6/30/2024	5,050	-5,867	-3,979	-3,241	N/A
3/31/2024	5,153	-5,968	-3,672	-2,882	N/A
12/31/2023	6,848	-4,714	-3,825	-3,118	N/A
9/30/2023	9,121	-3,466	-2,657	-2,078	N/A
6/30/2023	10,654	1,207	-754	-226	N/A
3/31/2023	15,059	4,784	612	993	N/A
12/31/2022	19,263	8,362	4,581	4,981	N/A
9/30/2022	21,390	11,765	6,201	6,629	N/A
6/30/2022	22,995	14,055	9,215	9,653	N/A
3/31/2022	22,600	14,638	13,031	13,412	N/A
12/31/2021	18,471	12,202	13,336	13,620	N/A
9/30/2021	11,831	7,061	11,386	11,574	N/A
6/30/2021	7,019	3,495	9,083	9,191	N/A
3/31/2021	2,732	598	5,007	5,104	N/A
12/31/2020	803	-747	1,959	2,027	N/A
9/30/2020	246	-597	613	664	N/A
6/30/2020	106	-488	-374	-336	N/A
3/31/2020	52	-505	-451	-421	N/A
12/31/2019	60	-514	-491	-459	N/A
9/30/2019	82	-535	-489	-451	N/A
6/30/2019	106	-499	-482	-424	N/A
3/31/2019	122	-459	-445	-364	N/A
12/31/2018	135	-402	-437	-331	N/A
9/30/2018	192	-299	-447	-343	N/A
6/30/2018	192	-280	N/A	-305	N/A
3/31/2018	199	-266	N/A	-350	N/A
12/31/2017	206	-270	N/A	-331	N/A
12/31/2016	108	-230	N/A	67	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1MRNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1MRNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1MRNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1MRNA's revenue (6.7% per year) is forecast to grow faster than the Italian market (4.1% per year).

High Growth Revenue: 1MRNA's revenue (6.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1MRNA is forecast to be unprofitable in 3 years.

Moderna Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna, Inc. Provides Sales Guidance for the Year 2023

Recent updates

Third quarter 2024 earnings released: EPS: US$0.034 (vs US$9.53 loss in 3Q 2023)

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024